Inflamación

5-HTP is the direct serotonin precursor used in amino acid therapy protocols for addiction and craving reduction. Preclinical and early clinical research supports its use in reducing cravings for alcohol, carbohydrates, and nicotine by restoring serotonergic tone depleted by addictive substances. A double-blind study in obese women found 5-HTP (900 mg/day) significantly reduced carbohydrate craving and intake.

Dopamine depletion is central to withdrawal and craving in substance use disorders, and tyrosine as a dopamine precursor has been studied in this context. Tyrosine depletion studies show cue-induced alcohol urging increases when dopaminergic tone is lowered. Direct supplementation RCTs in addiction are limited, and evidence is mechanistically suggestive rather than conclusive.

Agmatine is a decarboxylated arginine metabolite functioning as an endogenous neurotransmitter with preclinical evidence for reducing opioid and alcohol self-administration and tolerance. Multiple animal studies show agmatine inhibits ethanol self-administration via imidazoline I1/I2 receptor mechanisms and reduces opioid tolerance. Preclinical evidence is substantial; human clinical trials for craving remain limited.

Preclinical studies show BCP reduces voluntary alcohol intake, attenuates ethanol-induced conditioned place preference, and decreases motivation for palatable food in rodent models via CB2 receptor activation. One small human RCT examined BCP's effect on food addiction behaviors.

Chromium supplementation has been specifically studied for carbohydrate cravings in both clinical trials of atypical depression and food intake studies in overweight adults. Two published RCTs demonstrate reductions in carbohydrate cravings and carbohydrate-driven eating behavior with chromium. The mechanism is linked to insulin sensitization and serotonin/dopamine pathway modulation.

Chromium picolinate has been studied for carbohydrate cravings (particularly in atypical depression and binge eating disorder) and shows clinical signals for reducing compulsive food craving. Preclinical research also indicates chromium may modulate the dopaminergic reward system relevant to substance addiction. Human evidence is limited to food-related cravings rather than substance addiction.

A narrative review of nine clinical trials (Wignall & Brown, 2014, Am J Drug Alcohol Abuse) found citicoline appears to decrease craving and is associated with reduction in cocaine use at high doses in patients with bipolar disorder and cocaine dependence. Limited data also suggest benefit in alcohol and cannabis dependence. Evidence is promising but the overall body of human clinical evidence remains small and mixed.

Daidzin is the major active principle of the traditional Chinese herbal treatment for alcoholism (Radix puerariae/kudzu root), and is a potent selective inhibitor of mitochondrial aldehyde dehydrogenase (ALDH-2). It suppresses ethanol intake across multiple rodent species and models. Human trials of kudzu preparations show some reduction in alcohol consumption.

GABA is the primary inhibitory neurotransmitter in the CNS, with a well-established role in alcohol dependence and addiction. Alcohol acts at GABA-A receptors, and GABA system dysregulation underpins withdrawal craving and anxiety. GABA-modulating agents are core pharmacotherapy for alcohol withdrawal; supplemental GABA is used in integrative addiction protocols to reduce withdrawal anxiety and craving.

Gymnemic acids in GS reversibly suppress sweet taste receptors, decreasing the desire to consume sweet foods, reducing actual sugar intake in human crossover trials. Gymnemic acids have also been shown to reduce neural reward-circuit activation in response to sweet tastes, relevant to habitual sugar craving.

Kava (Piper methysticum) has traditional use in Pacific Island cultures as a social anxiolytic and has been investigated as an anticraving agent for alcohol and other substances. A preliminary clinical study (Cairney et al.; Savage et al.) supports kava's potential to reduce drug and alcohol craving via GABA-A receptor potentiation. Its kavalactones potentiate GABA-A receptor binding affinity.

Kudzu root extract has been used in Traditional Chinese Medicine for over 1,000 years to treat alcohol intoxication and reduce drinking. Multiple human RCTs demonstrate that standardized kudzu extract significantly reduces alcohol consumption in heavy drinkers. Its active isoflavones (daidzin, daidzein, puerarin) act via ALDH-2 inhibition and modulation of dopaminergic reward pathways.

L-glutamine is a conditionally essential amino acid used in amino acid therapy for addiction recovery. It serves as a glutamate/GABA precursor and blood sugar stabilizer, theorized to reduce cravings for alcohol, sugar, and stimulants by correcting neurotransmitter and glucose deficits in the brain. It is used in integrative addiction medicine as part of nutritional rehabilitation protocols.

Phenylalanine and tyrosine are the dietary precursors to dopamine, which mediates reward, motivation, and craving. Acute phenylalanine/tyrosine depletion (APTD) studies in humans reduce dopamine-mediated motivation and drug-seeking behavior, establishing the pathway's importance in addiction biology. L-phenylalanine supplementation has been proposed to support dopamine precursor availability in reward-deficiency states.

Serotonergic dysfunction, reflected in altered tryptophan levels, is implicated in alcohol dependence and substance craving. Human tryptophan depletion studies in alcohol-dependent individuals show that serotonin availability modulates craving and mood. Tryptophan enhancement has been shown to block stress-induced alcohol craving in binge drinkers.

L-tyrosine is the dietary precursor to dopamine and norepinephrine, neurotransmitters depleted by alcohol, stimulants (cocaine, methamphetamine, caffeine), and stress. Amino acid therapy protocols use l-tyrosine to replenish dopaminergic tone in early recovery from stimulant addiction and to reduce associated cravings. A nutrient supplement study including tyrosine reduced drug-withdrawal symptoms in recovering addicts.

Lithium orotate is the only form of lithium with a dedicated human clinical study in alcoholism. Sartori (1986) reported that 42 alcoholic patients treated with 150 mg/day lithium orotate for at least 6 months showed substantial reductions in alcohol relapse. No additional controlled studies have replicated this finding specifically for the orotate salt.

Lobeline was clinically investigated as a smoking cessation aid due to its nicotinic receptor activity. A phase 3 multicenter RCT (n=750) showed no significant benefit over placebo for smoking cessation (p=0.62). A Cochrane review concluded no long-term evidence supports lobeline for smoking cessation. Lobeline has also entered Phase 1 trials for methamphetamine addiction, where it was deemed safe.

NAC is a cysteine prodrug and glutathione precursor with well-documented evidence for reducing drug craving across multiple substance use disorders. A 2024 meta-analysis of 11 RCTs (n≈623) found NAC significantly reduced craving ratings (SMD −0.61) versus placebo across alcohol, cocaine, nicotine, amphetamine, and cannabis use disorders. Its mechanism involves rebalancing glutamate homeostasis in the nucleus accumbens and prefrontal cortex.

Passionflower (Passiflora incarnata) has demonstrated clinical efficacy as an adjunct to opiate withdrawal management. A double-blind RCT (Akhondzadeh et al., 2001; n=65) found clonidine plus passionflower extract superior to clonidine alone for managing mental symptoms of opiate withdrawal, including craving. Passionflower exerts its effects via GABAergic modulation.

Poppy (P. somniferum) opioid alkaloids are themselves central to the global opioid addiction crisis, and poppy seed tea use has been documented as causing opioid use disorder (OUD). Paradoxically, poppy-derived pharmaceutical opioids (buprenorphine, methadone) are also used to treat opioid dependence. The relationship is bidirectional and scientifically well-established.

Multiple clinical trials demonstrate that pregnenolone reduces stress- and cue-induced craving in alcohol use disorder and cocaine use disorder populations. A 2025 pilot RCT (Drug and Alcohol Dependence) found pregnenolone (300–500 mg/day) significantly reduced provoked craving and cocaine use over 8 weeks.

Puerarin, the most abundant isoflavone in kudzu root, has been investigated as a standalone anti-craving agent for alcohol. A pilot RCT found that puerarin (1,000 mg three times daily) significantly reduced alcohol intake in heavy drinkers without affecting urge to drink. Animal studies show puerarin reduces alcohol preference in alcohol-preferring rat strains.

Relora® has clinical evidence specifically for stress-related food cravings, particularly for sugary snacks. Pilot RCT data and open-label follow-up studies showed Relora diminished stress-related sugary snack cravings and promoted more healthful eating habits. No clinical evidence pertains to addictions in the substance-dependence sense; evidence is limited to cortisol-driven food cravings.

Saffron (Crocus sativus) and its active constituent crocin have demonstrated efficacy in reducing opioid craving and withdrawal symptoms in clinical trials. A 2020 RCT (n=60) found crocin (30 mg/day for 12 weeks) significantly improved craving scores (p=0.03) and withdrawal symptoms (p=0.01) in opioid patients on methadone maintenance. A systematic review of 8 studies confirmed saffron's efficacy for opioid withdrawal syndrome.

Mesembrine-type alkaloids have been flagged in the peer-reviewed pharmacology literature as showing promise for addiction disorders, linked to CB1 receptor blockade and absence of conditioned place preference in animal models. Traditional healers have used it to reduce cravings. No clinical trial in human addiction patients has been completed.

Alcohol use disorder is the primary risk factor for thiamine deficiency, and Wernicke-Korsakoff syndrome—a direct consequence of alcohol-related thiamine depletion—is a well-established neurological complication. Thiamine supplementation is standard of care in alcohol use disorder management to prevent and treat encephalopathy. The bidirectional relationship between chronic alcohol use and thiamine depletion is extensively documented.

California poppy is documented as a component of 'Kick Juice' formulas used in opiate withdrawal support in Western herbal medicine, and case reports describe its use in successfully weaning patients off opioids including oxycodone. Herbal Reality notes it is 'used in some programmes of opiate withdrawal.' No controlled clinical trials exist; evidence is limited to traditional herbalism practice and published case reports.

S. lateriflora has a traditional use for alcohol and tobacco withdrawal, documented in Encyclopedia.com and historical herbalist texts. Its GABAergic mechanism is pharmacologically relevant since GABA deficiency is implicated in substance craving. Eclectic physicians used it for 'delirium tremens.' No human clinical trials for addiction have been conducted.